Cisplatin, 5-Fluorouracil and high dose oral Leucovorin (PFL) with Methotrexate and Piritrexim as Neo-Adjuvant chemotherapy for head and neck cancer

Autor:	M. Collier, William R. Panje, J M McEvilly, Daniel J. Haraf, Mark Kozloff, N. J. Clendeninn, Everett E. Vokes, Allen G. Tybor, Ralph R. Weichselbaum, D. Goldman
Rok vydání:	1991
Předmět:	Oncology Cisplatin medicine.medical_specialty business.industry Head and neck cancer Phases of clinical research Piritrexim medicine.disease PFL Regimen Fluorouracil Internal medicine medicine Methotrexate business Neo adjuvant chemotherapy medicine.drug
Zdroj:	Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy ISBN: 9782817807843
DOI:	10.1007/978-2-8178-0782-9_14
Popis:	Studies in head and neck cancer at the University of Chicago have focused on the biochemical modulation of 5-Fluorouracil (5-FU). This has included the addition of high dose oral Leucovorin to the combination of Cisplatin and continuous infusion 5-FU (PFL). After establishing the pattern of toxicities, the recommended doses, and the efficacy of PFL in recurrent and/or metastatic disease [1], we treated patients with locally advanced disease with this PFL regimen and identified a high degree of activity [2, 3]. Piritrexim (PTX) is a MTX-analogue with single agent activity in head and neck cancer [4]. Since it is lipid soluble, it requires no active transportation and, therefore, may be able to overcome transport-related MTX resistance. In this phase II study, we added MTX and PTX to the PFL regimen (PFL-MP) hoping to further increase its activity.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d81683323d2b77863321c732ce779d68 https://doi.org/10.1007/978-2-8178-0782-9_14 Zobrazit plný text záznamu